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1215explain these ﬁndings. First, despite being the largest trial studying
intracoronary abciximab administration to date, AIDA STEMI
might have been underpowered to detect small differences in
clinical endpoints. Second, AIDA STEMI used an “all-comers”
design. However, it is possible that intracoronary abciximab might
only be advantageous in selected patients such as those with large
thrombus burden, total occlusion, or reduced ﬂow. AIDA STEMI
subgroup analyses, however, do not support a selective beneﬁt of
intracoronary over intravenous bolus abciximab in high-risk
patients. Third, the magnitude of the short-lived local effect of
intracoronary abciximab might not be enough to produce changes
in clinically meaningful endpoints, especially in the era of routine
preloading with other potent antiplatelet agents. Fourth, in the
AIDA STEMI trial, abciximab was injected through the guiding
catheter after wiring of the infarct-related artery. Although easy to
implement in clinical practice, this way of delivery might be
suboptimal in selected patients because of inadequate thrombus
penetration of abciximab and possible retrograde washout into the
ascending aorta. Novel application systems such as dedicated
perfusion catheters might exert superior efﬁcacy by allowing high
local drug concentrations in both vessel lumen and wall at the site
of thrombus with prolonged focal dwelling times (3).
In conclusion, AIDA STEMI does not support a possible
clinical superiority of intracoronary bolus delivery. (Abciximab IV
Versus IC in ST-Elevation Myocardial Infarction [AIDA
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2012;307:1817–26.Letters to the EditorPost-Conditioning at the Ischemic
Region of the Heart to Prevent
Acute Kidney Injury in Patients
With Non–ST-Segment Elevation
Myocardial InfarctionWe read with great interest the paper by Deftereos et al. (1). The
authors proposed a reduced effect of ischemic post-conditioning at
the ischemic region of the heart on the incidence of acute kidney
injury in patients with non–ST-segment elevation myocardial
infarction (non–STEMI) undergoing percutaneous coronary inter-
vention (PCI).
Accumulating evidence has suggested that prolonged ischemic
duration before reperfusion is a critical determinant of infarct size
and determines the infarct size–limiting effect by post-conditioning
(2–5). Protective stimulus induced by postconditioning has been
conﬁrmed in patients with STEMI within 6 to 12 h of symptom
onset to balloon time (6,7). However, the stimulus effectiveness by
post-conditioning for a more prolonged time after symptom onset
has not been elucidated. On the other hand, the remote organ used
for effective conditioning usually does not have pre-existing
ischemic injury in clinical practice (8,9).
In this study, they enrolled patients with non-STEMI undergoing
PCI within 72 h after symptom onset. This is obviously a wide range
of ischemia duration. Moreover, the mean symptom onset to balloon
time was not reported in the post-conditioning and control groups.
The potential difference in this time between these 2 groups may
result in evident confounding bias. Therefore, we are interested
to know whether the onset time to PCI was evenly distributed
between the post-conditioning group and the control group.
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We thank Dr. Zhou and colleagues their interest in our paper (1).
However, we would like to note that their arguments pertain to
remote ischemic pre-/post-conditioning with the heart as the
target organ (all their references are in regard to ischemic
conditioning for cardioprotection, not renoprotection). As a result,
we cannot really see how their rationale (e.g., regarding times of
cardiac ischemia in relation to the conditioning procedure) is of
relevance to our study. In any case, we do have the data on times
elapsed from the onset of ischemia to the coronary interventionand conditioning procedure. There was no signiﬁcant difference
between the 2 study arms: The median ischemia time was 10 h
(interquartile range: 8 to 12 h) in the remote conditioning group
versus 9 h (interquartile range: 7 to 13 h) in controls (p ¼ 0.294;
Mann-Whitney test).Spyridon Deftereos, MD
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Heart: Technical Concerns Beyond
the Protocol Algorithm
I read with great interest the paper by Deftereos et al. (1) that was
recently published in the Journal. The authors proposed a novel,
promising strategy to prevent acute kidney injury by ischemic post-
conditioning at the target lesion in patients with non–ST-segment
elevation myocardial infarction undergoing percutaneous coronary
intervention (PCI). However, nonsigniﬁcant cardioprotection was
obtained using regular protocol algorithms (4 cycles  60-s inﬂa-
tion/60-s deﬂation) in the clinical setting (2).
In addition to the cycles and time interval, accumulating evidence
has suggested that several technical issues may improve car-
dioprotection by postconditioning, such as the balloon position for
conditioning, the conditioning delay to ﬁrst inﬂation, and the
stenting technique. Thuny et al. (3) presumed that the post-
conditioning protocol must be performed upstream of the site of the
culprit lesion to reduce microembolisms. On the other hand, the
conditioning delay to ﬁrst inﬂation has been recognized as an
important determinant of reduction in infarct size (2). Prolongation
of delay from 10 to 30 s to 60 s (4,5) or 10 min (6) has been indicated
to result in the failure of cardioprotection by post-conditioning in
animal studies. In patients undergoing PCI, post-conditioning still
confers a cardioprotective effect with the delay ranging from 30 to
180 s (2) but not up to 5 min (7). In addition, the direct-stenting
technique also could attenuate coronary microembolization (8) and
may preserve the cardiac protection of post-conditioning in PCI
(9,10). Future clinical studies concerning post-conditioning in PCI
should standardize the maneuvers.
Nevertheless, these technical concerns were not reported clearly
in the study by Deftereos et al. (1), which is not the same as the
